For today, tomorrow, and the days to come

Person featured is compensated by Gilead.

For today, tomorrow, and the days to come

Person featured is compensated by Gilead.

For today, tomorrow, and the days to come

Person featured is compensated by Gilead.

For today, tomorrow, and the days to come

Person featured is compensated by Gilead.

Resistance Data Across 9 Clinical Trials

Explore the BIKTARVY resistance overview

Long-Term Treatment-Naïve Efficacy Data

Discover BIKTARVY 5-year efficacy data

5-Year Long-Term Safety and Tolerability Profile

Explore BIKTARVY safety data

The BIKTARVY Difference

BIKTARVY and DOVATO® (dolutegravir/lamivudine)

Select Differences in FDA-Approved Labeling and DHHS Guidelines

Explore now

Head-to-Head Safety Data from a Phase 4 Clinical Trial

Explore now

BIKTARVY and CABENUVA® (cabotegravir/rilpivirine)

Select Differences in FDA-Approved Labeling and DHHS Guidelines

Explore now

Head-to-Head Data from a Phase 3 Clinical Trial

Explore now

Learn More About Key Patient Populations

View BIKTARVY clinical data across diverse populations and stages of the HIV-1 treatment journey.

Explore real-world BIKTARVY study

SOURCE: IQVIA LAAD, August 2018 through July 2025*

*This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for the period of August 2018 through July 2025. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.

^†This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for July 2025. IQVIA expressly reserves all rights, including rights to copying, distribution, and republication.

DHHS, US Department of Health and Human Services; FDA, US Food and Drug Administration; PWH, people with HIV.

DOVATO® is a trademark of the ViiV Healthcare group of companies.

CABENUVA® is a trademark of the ViiV Healthcare group of companies.

Reference:

Data on file. Gilead Sciences, Inc.

You are leaving the BIKTARVY® website.

You are leaving the BIKTARVY® website.

For today, tomorrow, and the days to come

For today, tomorrow, and the days to come

For today, tomorrow, and the days to come

For today, tomorrow, and the days to come

Resistance Data Across 9 Clinical Trials

Long-Term Treatment-Naïve Efficacy Data

5-Year Long-Term Safety and Tolerability Profile

The BIKTARVY Difference

BIKTARVY and DOVATO® (dolutegravir/lamivudine)

Select Differences in FDA-Approved Labeling and DHHS Guidelines

Head-to-Head Safety Data from a Phase 4 Clinical Trial

BIKTARVY and CABENUVA® (cabotegravir/rilpivirine)

Select Differences in FDA-Approved Labeling and DHHS Guidelines

Head-to-Head Data from a Phase 3 Clinical Trial

Learn More About Key Patient Populations

Hispanic/Latine People With HIV

Treatment Experienced andNot Virologically Suppressed

Real-World Data in Treatment-Naïveand Treatment-Experienced Adults

People WithHIV Aged 50and Older

7 YEARS AS THE #1 PRESCRIBED* REGIMEN FOR PEOPLE STARTING AND SWITCHING HIV-1 TREATMENT WITH NEARLY 500,000 PWH† IN THE US ON THERAPY1

Fueled by the power of bictegravir1

See Dr. Joel Gallant and Dr. Calvin Cohen discuss more HIV topics:

You are leaving the BIKTARVY^® website.

You are leaving the BIKTARVY^® website.

Hispanic/Latine  People With HIV

Treatment Experienced and
Not Virologically Suppressed

Real-World Data in Treatment-Naïve
and Treatment-Experienced Adults

People With
HIV Aged 50
and Older

7 YEARS AS THE #1 PRESCRIBED^* REGIMEN FOR PEOPLE STARTING AND SWITCHING HIV-1 TREATMENT WITH NEARLY 500,000 PWH^† IN THE US ON THERAPY¹

Fueled by the power of bictegravir¹